Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
NCT06663072Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fulvestrant in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by University of Chicago. Primary endpoints: Objective Response Rate at 2 years and Safety at 8 months. Started Dec 2024; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT06663072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663072.